CN116687799A - Injection composition for removing wrinkles and preparation method thereof - Google Patents
Injection composition for removing wrinkles and preparation method thereof Download PDFInfo
- Publication number
- CN116687799A CN116687799A CN202310825559.7A CN202310825559A CN116687799A CN 116687799 A CN116687799 A CN 116687799A CN 202310825559 A CN202310825559 A CN 202310825559A CN 116687799 A CN116687799 A CN 116687799A
- Authority
- CN
- China
- Prior art keywords
- sodium hyaluronate
- parts
- molecular weight
- hyaluronic acid
- hexapeptide
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 238000002347 injection Methods 0.000 title claims abstract description 76
- 239000007924 injection Substances 0.000 title claims abstract description 76
- 230000037303 wrinkles Effects 0.000 title claims abstract description 55
- 239000000203 mixture Substances 0.000 title claims abstract description 51
- 238000002360 preparation method Methods 0.000 title abstract description 5
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 claims abstract description 102
- 229920002385 Sodium hyaluronate Polymers 0.000 claims abstract description 85
- 229940010747 sodium hyaluronate Drugs 0.000 claims abstract description 85
- YWIVKILSMZOHHF-QJZPQSOGSA-N sodium;(2s,3s,4s,5r,6r)-6-[(2s,3r,4r,5s,6r)-3-acetamido-2-[(2s,3s,4r,5r,6r)-6-[(2r,3r,4r,5s,6r)-3-acetamido-2,5-dihydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-2-carboxy-4,5-dihydroxyoxan-3-yl]oxy-5-hydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-3,4,5-trihydroxyoxane-2- Chemical compound [Na+].CC(=O)N[C@H]1[C@H](O)O[C@H](CO)[C@@H](O)[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@H](O[C@H]2[C@@H]([C@@H](O[C@H]3[C@@H]([C@@H](O)[C@H](O)[C@H](O3)C(O)=O)O)[C@H](O)[C@@H](CO)O2)NC(C)=O)[C@@H](C(O)=O)O1 YWIVKILSMZOHHF-QJZPQSOGSA-N 0.000 claims abstract description 85
- KIUKXJAPPMFGSW-DNGZLQJQSA-N (2S,3S,4S,5R,6R)-6-[(2S,3R,4R,5S,6R)-3-Acetamido-2-[(2S,3S,4R,5R,6R)-6-[(2R,3R,4R,5S,6R)-3-acetamido-2,5-dihydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-2-carboxy-4,5-dihydroxyoxan-3-yl]oxy-5-hydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-3,4,5-trihydroxyoxane-2-carboxylic acid Chemical compound CC(=O)N[C@H]1[C@H](O)O[C@H](CO)[C@@H](O)[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@H](O[C@H]2[C@@H]([C@@H](O[C@H]3[C@@H]([C@@H](O)[C@H](O)[C@H](O3)C(O)=O)O)[C@H](O)[C@@H](CO)O2)NC(C)=O)[C@@H](C(O)=O)O1 KIUKXJAPPMFGSW-DNGZLQJQSA-N 0.000 claims abstract description 58
- 229920002674 hyaluronan Polymers 0.000 claims abstract description 58
- 229960003160 hyaluronic acid Drugs 0.000 claims abstract description 58
- 239000000284 extract Substances 0.000 claims abstract description 48
- 240000001548 Camellia japonica Species 0.000 claims abstract description 47
- 235000018597 common camellia Nutrition 0.000 claims abstract description 47
- 239000003102 growth factor Substances 0.000 claims abstract description 41
- 239000002504 physiological saline solution Substances 0.000 claims abstract description 20
- -1 hexapeptide Chemical compound 0.000 claims abstract description 4
- 239000007853 buffer solution Substances 0.000 claims description 18
- 238000002156 mixing Methods 0.000 claims description 18
- 238000000034 method Methods 0.000 claims description 17
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 17
- 241001122767 Theaceae Species 0.000 claims description 15
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 claims description 14
- 239000002994 raw material Substances 0.000 claims description 14
- 230000005855 radiation Effects 0.000 claims description 12
- 230000001954 sterilising effect Effects 0.000 claims description 11
- 238000004659 sterilization and disinfection Methods 0.000 claims description 11
- 238000009835 boiling Methods 0.000 claims description 10
- 238000001914 filtration Methods 0.000 claims description 9
- 238000003756 stirring Methods 0.000 claims description 9
- 229930003231 vitamin Natural products 0.000 claims description 9
- 235000013343 vitamin Nutrition 0.000 claims description 9
- 239000011782 vitamin Substances 0.000 claims description 9
- 229940088594 vitamin Drugs 0.000 claims description 9
- 239000007972 injectable composition Substances 0.000 claims description 7
- 238000000605 extraction Methods 0.000 claims description 4
- 239000006286 aqueous extract Substances 0.000 claims description 3
- 238000004321 preservation Methods 0.000 claims description 3
- 102000008186 Collagen Human genes 0.000 abstract description 6
- 108010035532 Collagen Proteins 0.000 abstract description 6
- 229920001436 collagen Polymers 0.000 abstract description 6
- 238000011282 treatment Methods 0.000 abstract description 4
- 230000003796 beauty Effects 0.000 abstract description 3
- 239000007788 liquid Substances 0.000 abstract description 2
- 230000000052 comparative effect Effects 0.000 description 26
- 210000003491 skin Anatomy 0.000 description 26
- 230000000694 effects Effects 0.000 description 12
- 210000004027 cell Anatomy 0.000 description 10
- 239000000243 solution Substances 0.000 description 8
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 description 6
- 241000628997 Flos Species 0.000 description 6
- 241000699670 Mus sp. Species 0.000 description 6
- 238000004140 cleaning Methods 0.000 description 6
- 231100000263 cytotoxicity test Toxicity 0.000 description 5
- 230000008961 swelling Effects 0.000 description 5
- 238000012360 testing method Methods 0.000 description 5
- 238000002474 experimental method Methods 0.000 description 4
- 230000001815 facial effect Effects 0.000 description 4
- 238000011049 filling Methods 0.000 description 4
- 239000000463 material Substances 0.000 description 4
- 230000003020 moisturizing effect Effects 0.000 description 4
- 210000003205 muscle Anatomy 0.000 description 4
- ZZZCUOFIHGPKAK-UHFFFAOYSA-N D-erythro-ascorbic acid Natural products OCC1OC(=O)C(O)=C1O ZZZCUOFIHGPKAK-UHFFFAOYSA-N 0.000 description 3
- 229930003268 Vitamin C Natural products 0.000 description 3
- 206010000496 acne Diseases 0.000 description 3
- 239000007864 aqueous solution Substances 0.000 description 3
- 230000008901 benefit Effects 0.000 description 3
- 238000011161 development Methods 0.000 description 3
- 230000006870 function Effects 0.000 description 3
- 150000008442 polyphenolic compounds Chemical class 0.000 description 3
- 235000013824 polyphenols Nutrition 0.000 description 3
- 239000000047 product Substances 0.000 description 3
- 239000000126 substance Substances 0.000 description 3
- 210000001519 tissue Anatomy 0.000 description 3
- 235000019154 vitamin C Nutrition 0.000 description 3
- 239000011718 vitamin C Substances 0.000 description 3
- PVNIIMVLHYAWGP-UHFFFAOYSA-N Niacin Chemical compound OC(=O)C1=CC=CN=C1 PVNIIMVLHYAWGP-UHFFFAOYSA-N 0.000 description 2
- 230000009471 action Effects 0.000 description 2
- 235000001014 amino acid Nutrition 0.000 description 2
- 150000001413 amino acids Chemical class 0.000 description 2
- 230000033228 biological regulation Effects 0.000 description 2
- 239000008280 blood Substances 0.000 description 2
- 210000004369 blood Anatomy 0.000 description 2
- 239000003153 chemical reaction reagent Substances 0.000 description 2
- 230000008602 contraction Effects 0.000 description 2
- 210000000805 cytoplasm Anatomy 0.000 description 2
- 230000007812 deficiency Effects 0.000 description 2
- 210000004207 dermis Anatomy 0.000 description 2
- 229930003935 flavonoid Natural products 0.000 description 2
- 150000002215 flavonoids Chemical class 0.000 description 2
- 235000017173 flavonoids Nutrition 0.000 description 2
- 238000009499 grossing Methods 0.000 description 2
- 230000006872 improvement Effects 0.000 description 2
- 238000001727 in vivo Methods 0.000 description 2
- 230000007794 irritation Effects 0.000 description 2
- 239000011159 matrix material Substances 0.000 description 2
- 230000004089 microcirculation Effects 0.000 description 2
- 239000013642 negative control Substances 0.000 description 2
- 239000013641 positive control Substances 0.000 description 2
- 230000001737 promoting effect Effects 0.000 description 2
- LXNHXLLTXMVWPM-UHFFFAOYSA-N pyridoxine Chemical compound CC1=NC=C(CO)C(CO)=C1O LXNHXLLTXMVWPM-UHFFFAOYSA-N 0.000 description 2
- 150000003839 salts Chemical class 0.000 description 2
- 230000037393 skin firmness Effects 0.000 description 2
- 230000000638 stimulation Effects 0.000 description 2
- 231100000419 toxicity Toxicity 0.000 description 2
- 230000001988 toxicity Effects 0.000 description 2
- PFTAWBLQPZVEMU-DZGCQCFKSA-N (+)-catechin Chemical compound C1([C@H]2OC3=CC(O)=CC(O)=C3C[C@@H]2O)=CC=C(O)C(O)=C1 PFTAWBLQPZVEMU-DZGCQCFKSA-N 0.000 description 1
- TUSDEZXZIZRFGC-UHFFFAOYSA-N 1-O-galloyl-3,6-(R)-HHDP-beta-D-glucose Natural products OC1C(O2)COC(=O)C3=CC(O)=C(O)C(O)=C3C3=C(O)C(O)=C(O)C=C3C(=O)OC1C(O)C2OC(=O)C1=CC(O)=C(O)C(O)=C1 TUSDEZXZIZRFGC-UHFFFAOYSA-N 0.000 description 1
- 241000251468 Actinopterygii Species 0.000 description 1
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 1
- 208000002197 Ehlers-Danlos syndrome Diseases 0.000 description 1
- 102000009024 Epidermal Growth Factor Human genes 0.000 description 1
- 101800003838 Epidermal growth factor Proteins 0.000 description 1
- 208000010201 Exanthema Diseases 0.000 description 1
- 239000001263 FEMA 3042 Substances 0.000 description 1
- 108050007372 Fibroblast Growth Factor Proteins 0.000 description 1
- 102000018233 Fibroblast Growth Factor Human genes 0.000 description 1
- IAJILQKETJEXLJ-UHFFFAOYSA-N Galacturonsaeure Natural products O=CC(O)C(O)C(O)C(O)C(O)=O IAJILQKETJEXLJ-UHFFFAOYSA-N 0.000 description 1
- 229920002683 Glycosaminoglycan Polymers 0.000 description 1
- 229930195725 Mannitol Natural products 0.000 description 1
- OVRNDRQMDRJTHS-UHFFFAOYSA-N N-acelyl-D-glucosamine Natural products CC(=O)NC1C(O)OC(CO)C(O)C1O OVRNDRQMDRJTHS-UHFFFAOYSA-N 0.000 description 1
- OVRNDRQMDRJTHS-FMDGEEDCSA-N N-acetyl-beta-D-glucosamine Chemical compound CC(=O)N[C@H]1[C@H](O)O[C@H](CO)[C@@H](O)[C@@H]1O OVRNDRQMDRJTHS-FMDGEEDCSA-N 0.000 description 1
- MBLBDJOUHNCFQT-LXGUWJNJSA-N N-acetylglucosamine Natural products CC(=O)N[C@@H](C=O)[C@@H](O)[C@H](O)[C@H](O)CO MBLBDJOUHNCFQT-LXGUWJNJSA-N 0.000 description 1
- 108010025020 Nerve Growth Factor Proteins 0.000 description 1
- 102000015336 Nerve Growth Factor Human genes 0.000 description 1
- 206010067482 No adverse event Diseases 0.000 description 1
- 206010033799 Paralysis Diseases 0.000 description 1
- LRBQNJMCXXYXIU-PPKXGCFTSA-N Penta-digallate-beta-D-glucose Natural products OC1=C(O)C(O)=CC(C(=O)OC=2C(=C(O)C=C(C=2)C(=O)OC[C@@H]2[C@H]([C@H](OC(=O)C=3C=C(OC(=O)C=4C=C(O)C(O)=C(O)C=4)C(O)=C(O)C=3)[C@@H](OC(=O)C=3C=C(OC(=O)C=4C=C(O)C(O)=C(O)C=4)C(O)=C(O)C=3)[C@H](OC(=O)C=3C=C(OC(=O)C=4C=C(O)C(O)=C(O)C=4)C(O)=C(O)C=3)O2)OC(=O)C=2C=C(OC(=O)C=3C=C(O)C(O)=C(O)C=3)C(O)=C(O)C=2)O)=C1 LRBQNJMCXXYXIU-PPKXGCFTSA-N 0.000 description 1
- 206010040880 Skin irritation Diseases 0.000 description 1
- 229930003448 Vitamin K Natural products 0.000 description 1
- 230000002159 abnormal effect Effects 0.000 description 1
- 239000004480 active ingredient Substances 0.000 description 1
- 239000000853 adhesive Substances 0.000 description 1
- 230000001070 adhesive effect Effects 0.000 description 1
- AEMOLEFTQBMNLQ-WAXACMCWSA-N alpha-D-glucuronic acid Chemical compound O[C@H]1O[C@H](C(O)=O)[C@@H](O)[C@H](O)[C@H]1O AEMOLEFTQBMNLQ-WAXACMCWSA-N 0.000 description 1
- 210000004381 amniotic fluid Anatomy 0.000 description 1
- 208000022531 anorexia Diseases 0.000 description 1
- 230000003712 anti-aging effect Effects 0.000 description 1
- 230000001153 anti-wrinkle effect Effects 0.000 description 1
- 239000003963 antioxidant agent Substances 0.000 description 1
- 230000003078 antioxidant effect Effects 0.000 description 1
- 235000006708 antioxidants Nutrition 0.000 description 1
- 230000006907 apoptotic process Effects 0.000 description 1
- 210000001188 articular cartilage Anatomy 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 description 1
- ADRVNXBAWSRFAJ-UHFFFAOYSA-N catechin Natural products OC1Cc2cc(O)cc(O)c2OC1c3ccc(O)c(O)c3 ADRVNXBAWSRFAJ-UHFFFAOYSA-N 0.000 description 1
- 235000005487 catechin Nutrition 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 238000006243 chemical reaction Methods 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 229950001002 cianidanol Drugs 0.000 description 1
- 230000037319 collagen production Effects 0.000 description 1
- 238000004891 communication Methods 0.000 description 1
- 210000002808 connective tissue Anatomy 0.000 description 1
- 230000001276 controlling effect Effects 0.000 description 1
- 238000002316 cosmetic surgery Methods 0.000 description 1
- 210000000695 crystalline len Anatomy 0.000 description 1
- 231100000135 cytotoxicity Toxicity 0.000 description 1
- 230000003013 cytotoxicity Effects 0.000 description 1
- 206010061428 decreased appetite Diseases 0.000 description 1
- 230000004069 differentiation Effects 0.000 description 1
- 125000000600 disaccharide group Chemical group 0.000 description 1
- 239000003814 drug Substances 0.000 description 1
- 230000002900 effect on cell Effects 0.000 description 1
- 230000009982 effect on human Effects 0.000 description 1
- 210000004177 elastic tissue Anatomy 0.000 description 1
- 239000003792 electrolyte Substances 0.000 description 1
- 229940116977 epidermal growth factor Drugs 0.000 description 1
- 238000011156 evaluation Methods 0.000 description 1
- 201000005884 exanthem Diseases 0.000 description 1
- 210000001723 extracellular space Anatomy 0.000 description 1
- 229940126864 fibroblast growth factor Drugs 0.000 description 1
- 239000000945 filler Substances 0.000 description 1
- 210000001061 forehead Anatomy 0.000 description 1
- 150000004676 glycans Chemical class 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- 229910052739 hydrogen Inorganic materials 0.000 description 1
- 239000001257 hydrogen Substances 0.000 description 1
- 125000002887 hydroxy group Chemical group [H]O* 0.000 description 1
- 238000000338 in vitro Methods 0.000 description 1
- 230000001050 lubricating effect Effects 0.000 description 1
- 238000005461 lubrication Methods 0.000 description 1
- 238000012423 maintenance Methods 0.000 description 1
- 239000000594 mannitol Substances 0.000 description 1
- 235000010355 mannitol Nutrition 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 230000004118 muscle contraction Effects 0.000 description 1
- 229950006780 n-acetylglucosamine Drugs 0.000 description 1
- 229940053128 nerve growth factor Drugs 0.000 description 1
- 230000002232 neuromuscular Effects 0.000 description 1
- 235000001968 nicotinic acid Nutrition 0.000 description 1
- 229960003512 nicotinic acid Drugs 0.000 description 1
- 239000011664 nicotinic acid Substances 0.000 description 1
- 231100000344 non-irritating Toxicity 0.000 description 1
- 235000015097 nutrients Nutrition 0.000 description 1
- 210000000056 organ Anatomy 0.000 description 1
- 210000003463 organelle Anatomy 0.000 description 1
- 230000003204 osmotic effect Effects 0.000 description 1
- 230000002093 peripheral effect Effects 0.000 description 1
- 239000012466 permeate Substances 0.000 description 1
- SHUZOJHMOBOZST-UHFFFAOYSA-N phylloquinone Natural products CC(C)CCCCC(C)CCC(C)CCCC(=CCC1=C(C)C(=O)c2ccccc2C1=O)C SHUZOJHMOBOZST-UHFFFAOYSA-N 0.000 description 1
- 230000035790 physiological processes and functions Effects 0.000 description 1
- 210000002826 placenta Anatomy 0.000 description 1
- 229920001282 polysaccharide Polymers 0.000 description 1
- 239000005017 polysaccharide Substances 0.000 description 1
- 230000035755 proliferation Effects 0.000 description 1
- 102000004169 proteins and genes Human genes 0.000 description 1
- 108090000623 proteins and genes Proteins 0.000 description 1
- RADKZDMFGJYCBB-UHFFFAOYSA-N pyridoxal hydrochloride Natural products CC1=NC=C(CO)C(C=O)=C1O RADKZDMFGJYCBB-UHFFFAOYSA-N 0.000 description 1
- 206010037844 rash Diseases 0.000 description 1
- 230000001172 regenerating effect Effects 0.000 description 1
- 230000001105 regulatory effect Effects 0.000 description 1
- 230000003716 rejuvenation Effects 0.000 description 1
- 230000008439 repair process Effects 0.000 description 1
- 230000004044 response Effects 0.000 description 1
- 229930182490 saponin Natural products 0.000 description 1
- 235000017709 saponins Nutrition 0.000 description 1
- 150000007949 saponins Chemical class 0.000 description 1
- 210000004927 skin cell Anatomy 0.000 description 1
- 230000036556 skin irritation Effects 0.000 description 1
- 231100000475 skin irritation Toxicity 0.000 description 1
- 239000011734 sodium Substances 0.000 description 1
- 238000010254 subcutaneous injection Methods 0.000 description 1
- 239000007929 subcutaneous injection Substances 0.000 description 1
- 230000004083 survival effect Effects 0.000 description 1
- 210000001179 synovial fluid Anatomy 0.000 description 1
- 235000015523 tannic acid Nutrition 0.000 description 1
- 229920002258 tannic acid Polymers 0.000 description 1
- LRBQNJMCXXYXIU-NRMVVENXSA-N tannic acid Chemical compound OC1=C(O)C(O)=CC(C(=O)OC=2C(=C(O)C=C(C=2)C(=O)OC[C@@H]2[C@H]([C@H](OC(=O)C=3C=C(OC(=O)C=4C=C(O)C(O)=C(O)C=4)C(O)=C(O)C=3)[C@@H](OC(=O)C=3C=C(OC(=O)C=4C=C(O)C(O)=C(O)C=4)C(O)=C(O)C=3)[C@@H](OC(=O)C=3C=C(OC(=O)C=4C=C(O)C(O)=C(O)C=4)C(O)=C(O)C=3)O2)OC(=O)C=2C=C(OC(=O)C=3C=C(O)C(O)=C(O)C=3)C(O)=C(O)C=2)O)=C1 LRBQNJMCXXYXIU-NRMVVENXSA-N 0.000 description 1
- 229940033123 tannic acid Drugs 0.000 description 1
- 231100000331 toxic Toxicity 0.000 description 1
- 230000002588 toxic effect Effects 0.000 description 1
- 238000002604 ultrasonography Methods 0.000 description 1
- VBEQCZHXXJYVRD-GACYYNSASA-N uroanthelone Chemical compound C([C@@H](C(=O)N[C@H](C(=O)N[C@@H](CS)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CS)C(=O)N[C@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)NCC(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(=O)N[C@@H](CO)C(=O)NCC(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CS)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCNC(N)=N)C(O)=O)C(C)C)[C@@H](C)O)NC(=O)[C@H](CO)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CO)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@@H](NC(=O)[C@H](CC=1NC=NC=1)NC(=O)[C@H](CCSC)NC(=O)[C@H](CS)NC(=O)[C@@H](NC(=O)CNC(=O)CNC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CS)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)CNC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CO)NC(=O)[C@H](CO)NC(=O)[C@H]1N(CCC1)C(=O)[C@H](CS)NC(=O)CNC(=O)[C@H]1N(CCC1)C(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CO)NC(=O)[C@@H](N)CC(N)=O)C(C)C)[C@@H](C)CC)C1=CC=C(O)C=C1 VBEQCZHXXJYVRD-GACYYNSASA-N 0.000 description 1
- 235000019158 vitamin B6 Nutrition 0.000 description 1
- 239000011726 vitamin B6 Substances 0.000 description 1
- 235000019168 vitamin K Nutrition 0.000 description 1
- 239000011712 vitamin K Substances 0.000 description 1
- 150000003721 vitamin K derivatives Chemical class 0.000 description 1
- 229940011671 vitamin b6 Drugs 0.000 description 1
- 229940046010 vitamin k Drugs 0.000 description 1
- 210000004127 vitreous body Anatomy 0.000 description 1
- RKQOSDAEEGPRER-UHFFFAOYSA-L zinc diethyldithiocarbamate Chemical compound [Zn+2].CCN(CC)C([S-])=S.CCN(CC)C([S-])=S RKQOSDAEEGPRER-UHFFFAOYSA-L 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/72—Cosmetics or similar toiletry preparations characterised by the composition containing organic macromolecular compounds
- A61K8/73—Polysaccharides
- A61K8/735—Mucopolysaccharides, e.g. hyaluronic acid; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
- A61K8/33—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing oxygen
- A61K8/34—Alcohols
- A61K8/345—Alcohols containing more than one hydroxy group
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
- A61K8/64—Proteins; Peptides; Derivatives or degradation products thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/96—Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution
- A61K8/97—Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution from algae, fungi, lichens or plants; from derivatives thereof
- A61K8/9783—Angiosperms [Magnoliophyta]
- A61K8/9789—Magnoliopsida [dicotyledons]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L27/00—Materials for grafts or prostheses or for coating grafts or prostheses
- A61L27/14—Macromolecular materials
- A61L27/20—Polysaccharides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L27/00—Materials for grafts or prostheses or for coating grafts or prostheses
- A61L27/14—Macromolecular materials
- A61L27/22—Polypeptides or derivatives thereof, e.g. degradation products
- A61L27/227—Other specific proteins or polypeptides not covered by A61L27/222, A61L27/225 or A61L27/24
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L27/00—Materials for grafts or prostheses or for coating grafts or prostheses
- A61L27/36—Materials for grafts or prostheses or for coating grafts or prostheses containing ingredients of undetermined constitution or reaction products thereof, e.g. transplant tissue, natural bone, extracellular matrix
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L27/00—Materials for grafts or prostheses or for coating grafts or prostheses
- A61L27/50—Materials characterised by their function or physical properties, e.g. injectable or lubricating compositions, shape-memory materials, surface modified materials
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L27/00—Materials for grafts or prostheses or for coating grafts or prostheses
- A61L27/50—Materials characterised by their function or physical properties, e.g. injectable or lubricating compositions, shape-memory materials, surface modified materials
- A61L27/54—Biologically active materials, e.g. therapeutic substances
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
- A61Q19/00—Preparations for care of the skin
- A61Q19/08—Anti-ageing preparations
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2800/00—Properties of cosmetic compositions or active ingredients thereof or formulation aids used therein and process related aspects
- A61K2800/80—Process related aspects concerning the preparation of the cosmetic composition or the storage or application thereof
- A61K2800/91—Injection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L2400/00—Materials characterised by their function or physical properties
- A61L2400/06—Flowable or injectable implant compositions
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Chemical & Material Sciences (AREA)
- Dermatology (AREA)
- Medicinal Chemistry (AREA)
- Oral & Maxillofacial Surgery (AREA)
- Transplantation (AREA)
- Birds (AREA)
- Engineering & Computer Science (AREA)
- Biomedical Technology (AREA)
- Botany (AREA)
- Gerontology & Geriatric Medicine (AREA)
- Emergency Medicine (AREA)
- Biotechnology (AREA)
- Mycology (AREA)
- Microbiology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Molecular Biology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines Containing Plant Substances (AREA)
- Medicinal Preparation (AREA)
Abstract
The application discloses an injection composition for removing wrinkles and a preparation method thereof, belonging to the technical field of beauty treatment liquid. The application discloses an injection composition for removing wrinkles, which comprises hyaluronic acid, sodium hyaluronate, growth factors, hexapeptide, glycerol, physiological saline and camellia extract. The components in the application are matched with each other to play a role in synergy, have efficacy on skin with different folds, and can stimulate the skin to generate collagen so as to maintain the long-acting wrinkle removing function. Meanwhile, the injection composition has higher stability and can be stably stored for 2-3 years.
Description
Technical Field
The application belongs to the technical field of beauty treatment liquid, and particularly relates to an injection composition for removing wrinkles and a preparation method thereof.
Background
With the improvement of the living standard of people, people loving beauty are more and more, and particularly, the face beautifying treatment is carried out. Face rejuvenation has been the key area of development in the whole industry as an important search direction in orthopaedics, and for this reason, various plastic surgery modes have been explored to improve facial wrinkles and skin pits. The main treatments include laser, photon, radio frequency, ultrasound, electron injection, roller microneedle, etc. In recent years, based on the rapid development of material science, tissue engineering and regenerative medicine are rapidly developed, and various materials also fully affect various medical fields. Medical cosmetology is a medical discipline which is rapidly developed in the last decade, the economic benefit brought by the medical cosmetology is not underestimated, and the filling material is one of the most important directions of the medical cosmetology neighborhood.
The main filling injection material is hyaluronic acid at present, and subcutaneous injection of hyaluronic acid and salts thereof can fill skin tissues, remove wrinkles and fill skin contours. Hyaluronic acid and its salts, however, do not stimulate collagen production by skin cells and have a limited duration of action, requiring repeated injections.
Disclosure of Invention
The application provides an injection composition for removing wrinkles and a preparation method thereof, which are used for solving the problems of short action time, lower efficacy and the like of an injection taking hyaluronic acid as a main filler in the prior art.
In a first aspect, the application provides an injection composition for removing wrinkles, comprising hyaluronic acid, sodium hyaluronate, growth factors, hexapeptide, glycerol, physiological saline and camellia extract.
Further, in a preferred scheme of the application, the mass ratio of the hyaluronic acid to the camellia extract is 1-4:1-3:1.
Further, in a preferred embodiment of the present application, the mass ratio of the growth factor, the hexapeptide and the glycerol is 0.01-0.5:0.01-0.1:5-10, and the mass fraction of the physiological saline is 50-95%.
Further, in a preferred embodiment of the present application, the present application comprises the following raw materials in parts by weight:
1 to 4 parts of hyaluronic acid, 1 to 3 parts of sodium hyaluronate, 0.01 to 0.5 part of growth factor, 0.01 to 0.1 part of hexapeptide, 5 to 10 parts of glycerol, 50 to 95 parts of normal saline and 1 part of camellia extract.
Further, in a preferred embodiment of the present application, the present application comprises the following raw materials in parts by weight:
4 parts of hyaluronic acid, 1 part of sodium hyaluronate, 0.5 part of growth factor, 0.01 part of hexapeptide, 10 parts of glycerol, 80 parts of normal saline and 1 part of camellia extract.
In a preferred embodiment of the present application, the camellia extract is a camellia aqueous extract obtained by mixing with water, boiling extraction, filtration, and freeze preservation.
Further, in a preferred scheme of the application, the sodium hyaluronate comprises medium molecular weight sodium hyaluronate and small molecular weight sodium hyaluronate with a mass ratio of 1:10-20, wherein the molecular weight of the medium molecular weight sodium hyaluronate is 100 ten thousand-120 ten thousand daltons, and the molecular weight of the small molecular weight sodium hyaluronate is 3000-8000 daltons.
Further, in a preferred embodiment of the present application, the hyaluronic acid has a molecular weight of 10000 to 30000 daltons.
Further, in a preferred embodiment of the present application, vitamins are also included.
In a second aspect, the present application provides a method for preparing the injection composition for removing wrinkles according to any one of the first aspect, comprising the steps of:
preparing tea flower extract, mixing and stirring the tea flower extract with glycerol, growth factors and physiological saline at the temperature of 5-10 ℃ to obtain a functional buffer solution;
after the hexapeptide and the sodium hyaluronate are uniformly mixed, hyaluronic acid and a functional buffer solution are added, and after radiation sterilization, the injection composition for removing wrinkles is prepared.
Compared with the prior art, the technical scheme provided by the embodiment of the application has at least the following advantages:
1. the injection composition for removing wrinkles disclosed by the application has good elasticity, adhesion performance and water retention performance, is mild and has no stimulation, and can not cause red swelling and pimple after being used for skin injection; has good biocompatibility, can adapt to the environment of skin, and realizes the rapid relaxation and paralysis of muscles in the skin, thereby realizing the long-acting wrinkle removal function and smoothing and flattening the skin.
2. The injection composition for removing wrinkles disclosed by the application can be used for filling skin wrinkles, increasing skin firmness, improving facial contours and the like. Compared with the existing injection products, the skin can generate more natural plump feel and youthful effect, and can tighten loose and drooping skin by filling and lifting the skin, effectively relieve the tension of facial neuromuscular, smooth the skin and relieve facial dynamic wrinkles.
Detailed Description
For the purpose of making the objects, technical solutions and advantages of the embodiments of the present application more apparent, the technical solutions in the embodiments of the present application will be clearly and completely described below, and it is apparent that the described embodiments are some embodiments of the present application, but not all embodiments. All other embodiments, which can be made by those skilled in the art based on the embodiments of the application without making any inventive effort, are intended to be within the scope of the application.
Unless otherwise specifically indicated, the various raw materials, reagents, instruments, equipment and the like used in the present application are commercially available or may be prepared by existing methods.
In a first aspect, the application provides an injection composition for removing wrinkles, comprising hyaluronic acid, sodium hyaluronate, growth factors, hexapeptide, glycerol, physiological saline and camellia extract.
In the application, hyaluronic acid and hexapeptide are mixed and injected, so that excessive sunken wrinkles can be eliminated, and the hyaluronic acid and hexapeptide are mixed and injected with growth factors, so that wrinkles such as dry lines caused by excessive water deficiency or collagen loss can be filled, and collagen growth can be stimulated. Meanwhile, the addition of hyaluronic acid greatly increases the pulling capacity and the stability of the injection composition, and the stability of the injection composition can be kept for two to three years. In the application, the sodium hyaluronate mainly plays roles of moisturizing and promoting hyaluronic acid to generate effect, and the sodium hyaluronate can permeate into dermis, so that the health care effect of promoting blood microcirculation is achieved, the skin can absorb nutrient substances, and the anti-wrinkle performance is improved. In the application, the sodium hyaluronate can be matched with the camellia extracting solution, and the components such as vitamins, polyphenols, flavonoids, amino acids and the like in the camellia extracting solution are driven to be fully absorbed by the skin. In the application, the growth factors have the functions of regulating and controlling the growth and development of cells, can accelerate the apoptosis of aged cells after injection, promote the differentiation of the growth cells, and simultaneously open the microcirculation of blood, thereby avoiding the situation of local red swelling and rash of human bodies caused by injection. In the application, the hexapeptide and the growth factor act together, so that the contraction of muscles can be slowed down, fine lines caused by the contraction of the muscles can be reduced, the collagen elasticity can be effectively organized, the activity of the collagen is increased, and the effects of smoothing wrinkles and improving relaxation are achieved. On the basis, the growth factors and the camellia extract act, so that on one hand, the stimulation performance of the hexapeptide is buffered, and on the other hand, the generation of collagen is promoted.
Hyaluronic acid, also known as hyaluronic acid, of formula (C 14 H 21 NO 11 ) n Is disaccharide unit glycosaminoglycan composed of D-glucuronic acid and N-acetylglucosamine. Is the main component of connective tissue such as human body cell matrix, eye vitreous body, joint synovial fluid, etc., and plays important physiological functions of water retention, extracellular space maintenance, osmotic pressure regulation, lubrication and cell repair promotion in vivo. The hyaluronic acid molecule contains a large number of carboxyl and hydroxyl groups, and intramolecular and intermolecular hydrogen bonds are formed in the aqueous solution, so that the hyaluronic acid molecule has strong water retention effect and can be combined with water of more than 400 times of the hyaluronic acid molecule; at higher concentrations, complex tertiary phases are formed due to intermolecular interactionsThe network structure, the aqueous solution of which has significant viscoelasticity. Hyaluronic acid is used as a main component of intercellular matrix, directly participates in the regulation and control of electrolyte communication inside and outside cells, and plays a role of a filter for physical and molecular information.
Sodium hyaluronate with chemical formula (C) 14 H 20 NO 11 Na) n Is widely applied to tissues and organs such as placenta, amniotic fluid, crystalline lens, articular cartilage, dermis layer of skin, etc. It is distributed in cytoplasm and cell interstitium, and has lubricating and nourishing effects on cells and organelles contained in the cytoplasm and the cell interstitium. In the application, the sodium hyaluronate can also be used as a viscous agent, so that the whole injection composition forms gel, can exist stably before injection, and can play an anti-aging role after injection.
In the present application, the growth factors may be epidermal growth factor, platelet growth factor, fibroblast growth factor, nerve growth factor, etc. based on the corresponding functions, proper growth factors are selected.
In the application, the hexapeptide is also called as botulinum, and the active hexapeptide can effectively relieve and inhibit the contraction and activity of forehead head-up lines, eye fish tail fine lines and peripheral muscles, help the muscles relax, and enable the skin elastic tissues to recover soft and smooth lines.
In the application, the camellia extracting solution can be extracting solution of camellia, puer tea and the rest camellia, preferably camellia extracting solution, and the active ingredients comprise protein, tea polyphenol, tea polysaccharide, active antioxidant substances, polyphenols, flavonoids, saponins, catechin, vitamin C, tannic acid, amino acid and the like, so that the skin firmness and moisture can be kept, the problems of skin fine lines and water deficiency can be improved, the skin brightness can be improved, and the moisturizing sense can be improved.
Preferably, the mass ratio of the hyaluronic acid to the sodium hyaluronate to the camellia extracting solution is 1-4:1-3:1.
More preferably, the mass ratio of hyaluronic acid, sodium hyaluronate and camellia extract is 4:1:1.
Preferably, the mass ratio of the growth factor to the hexapeptide to the glycerol is 0.01-0.5:0.01-0.1:5-10, and the mass fraction of the physiological saline is 50-95%.
In the application, the effect can be achieved under the condition of low content of the growth factors and the hexapeptide, and the growth factors and the hexapeptide do not need to be supplemented, thereby greatly reducing the cost of the product.
Preferably, the adhesive comprises the following raw materials in parts by weight:
1 to 4 parts of hyaluronic acid, 1 to 3 parts of sodium hyaluronate, 0.01 to 0.5 part of growth factor, 0.01 to 0.1 part of hexapeptide, 5 to 10 parts of glycerol, 50 to 95 parts of normal saline and 1 part of camellia extract.
Most preferably, in a preferred embodiment of the present application, the composition comprises the following raw materials in parts by weight:
4 parts of hyaluronic acid, 1 part of sodium hyaluronate, 0.5 part of growth factor, 0.01 part of hexapeptide, 10 parts of glycerol, 80 parts of normal saline and 1 part of camellia extract.
Preferably, the camellia extract is a camellia aqueous extract, and is obtained by mixing the camellia extract with water, boiling extraction, filtration and freeze preservation.
Wherein the mass ratio of the camellia to the water is 1-3:20, and the boiling extraction time is 30-45 min.
Preferably, the sodium hyaluronate comprises medium molecular weight sodium hyaluronate and small molecular weight sodium hyaluronate with the mass ratio of 1:10-20, wherein the molecular weight of the medium molecular weight sodium hyaluronate is 100 ten thousand-120 ten thousand daltons, and the molecular weight of the small molecular weight sodium hyaluronate is 3000-8000 daltons.
Preferably, in a preferred embodiment of the present application, the hyaluronic acid has a molecular weight of 10000 to 30000 daltons.
Preferably, in a preferred embodiment of the present application, vitamins are also included.
The vitamins in the application can be vitamin C, vitamin B6, vitamin K or nicotinic acid, etc., the dosage of the vitamins is preferably 0 to 0.6 percent, and the vitamins can be adjusted according to the dosage of the camellia extract. When the content of the camellia extract is high, the use of vitamins can be properly reduced, and when the content of the camellia extract is low, the use amount of vitamins can be properly increased.
In a second aspect, the present application provides a method for preparing the injection composition for removing wrinkles according to any one of the first aspect, comprising the steps of:
preparing tea flower extract, mixing and stirring the tea flower extract with glycerol, growth factors and physiological saline at the temperature of 5-10 ℃ to obtain a functional buffer solution;
after the hexapeptide and the sodium hyaluronate are uniformly mixed, hyaluronic acid and a functional buffer solution are added, and after radiation sterilization, the injection composition for removing wrinkles is prepared.
In the present application, the radiation sterilization is performed by conventional means, and may be, but not limited to, the following: co (Co) 60 Radiation sterilization, wherein the radiation dose is 7-10 kGy.
The principles and features of the present application are described below in connection with the following examples, which are set forth to illustrate, but are not to be construed as limiting the scope of the application. The specific conditions are not noted in the examples and are carried out according to conventional conditions or conditions recommended by the manufacturer. The reagents or apparatus used were conventional products commercially available without the manufacturer's attention.
Example 1
The embodiment provides an injection composition for removing wrinkles, which comprises the following raw materials in parts by weight:
4 parts of hyaluronic acid, 1 part of sodium hyaluronate, 0.5 part of growth factor, 0.01 part of hexapeptide, 10 parts of glycerol, 80 parts of normal saline and 1 part of camellia extract.
Wherein the molecular weight of hyaluronic acid is 10000 dalton, the sodium hyaluronate comprises medium molecular weight sodium hyaluronate and small molecular weight sodium hyaluronate with the mass ratio of 1:10, the molecular weight of the medium molecular weight sodium hyaluronate is 100 kilodaltons, and the molecular weight of the small molecular weight sodium hyaluronate is 8000 dalton.
Wherein, the camellia extract is obtained by the following method: cleaning flos Camelliae Japonicae, mixing with 20 times of water, boiling for 30min, filtering, and freeze preserving.
The injection composition for removing wrinkles in this example was prepared by the following method:
preparing tea flower extract, mixing and stirring with glycerol, growth factors and physiological saline at 5 ℃ to obtain a functional buffer solution;
after the hexapeptide and the sodium hyaluronate are uniformly mixed, hyaluronic acid and a functional buffer solution are added, and after radiation sterilization, the injection composition for removing wrinkles is prepared.
Example 2
The embodiment provides an injection composition for removing wrinkles, which comprises the following raw materials in parts by weight:
1 part of hyaluronic acid, 3 parts of sodium hyaluronate, 0.5 part of growth factor, 0.1 part of hexapeptide, 5 parts of glycerol, 90 parts of normal saline and 1 part of camellia extract.
Wherein the molecular weight of hyaluronic acid is 30000 daltons, the sodium hyaluronate comprises medium molecular weight sodium hyaluronate and small molecular weight sodium hyaluronate with the mass ratio of 1:20, the molecular weight of the medium molecular weight sodium hyaluronate is 100 ten thousand daltons, and the molecular weight of the small molecular weight sodium hyaluronate is 3000 daltons.
Wherein, the camellia extract is obtained by the following method: cleaning flos Camelliae Japonicae, mixing with 10 times of water, boiling, extracting for 40min, filtering, and freeze preserving.
The injection composition for removing wrinkles in this example was prepared by the following method:
preparing tea flower extract, mixing and stirring with glycerol, growth factors and physiological saline at 5 ℃ to obtain a functional buffer solution;
after the hexapeptide and the sodium hyaluronate are uniformly mixed, hyaluronic acid and a functional buffer solution are added, and after radiation sterilization, the injection composition for removing wrinkles is prepared.
Example 3
The embodiment provides an injection composition for removing wrinkles, which comprises the following raw materials in parts by weight:
2 parts of hyaluronic acid, 2 parts of sodium hyaluronate, 0.1 part of growth factor, 0.05 part of hexapeptide, 8 parts of glycerol, 87 parts of normal saline and 1 part of camellia extract.
Wherein the molecular weight of hyaluronic acid is 20000 daltons, the sodium hyaluronate comprises medium molecular weight sodium hyaluronate and small molecular weight sodium hyaluronate with a mass ratio of 1:10, the molecular weight of the medium molecular weight sodium hyaluronate is 120 ten thousand daltons, and the molecular weight of the small molecular weight sodium hyaluronate is 8000 daltons.
Wherein, the camellia extract is obtained by the following method: cleaning flos Camelliae Japonicae, mixing with 10 times of water, boiling for 30min, filtering, and freeze preserving.
The injection composition for removing wrinkles in this example was prepared by the following method:
preparing tea flower extract, mixing and stirring with glycerol, growth factors and physiological saline at 10 ℃ to obtain a functional buffer solution;
after the hexapeptide and the sodium hyaluronate are uniformly mixed, hyaluronic acid and a functional buffer solution are added, and after radiation sterilization, the injection composition for removing wrinkles is prepared.
Example 4
The embodiment provides an injection composition for removing wrinkles, which comprises the following raw materials in parts by weight:
4 parts of hyaluronic acid, 3 parts of sodium hyaluronate, 0.5 part of growth factor, 0.01 part of hexapeptide, 8 parts of glycerol, 84 parts of normal saline and 1 part of camellia extract.
Wherein the molecular weight of hyaluronic acid is 15000 daltons, the sodium hyaluronate comprises medium molecular weight sodium hyaluronate and small molecular weight sodium hyaluronate with the mass ratio of 1:15, the molecular weight of the medium molecular weight sodium hyaluronate is 120 ten thousand daltons, and the molecular weight of the small molecular weight sodium hyaluronate is 5000 daltons.
Wherein, the camellia extract is obtained by the following method: cleaning flos Camelliae Japonicae, mixing with 15 times of water, boiling for 45min, filtering, and freeze preserving.
The injection composition for removing wrinkles in this example was prepared by the following method:
preparing tea flower extract, mixing and stirring with glycerol, growth factors and physiological saline at 6 ℃ to obtain a functional buffer solution;
after the hexapeptide and the sodium hyaluronate are uniformly mixed, hyaluronic acid and a functional buffer solution are added, and after radiation sterilization, the injection composition for removing wrinkles is prepared.
Example 5
The embodiment provides an injection composition for removing wrinkles, which comprises the following raw materials in parts by weight:
3 parts of hyaluronic acid, 2 parts of sodium hyaluronate, 0.25 part of growth factor, 0.05 part of hexapeptide, 7 parts of glycerol, 87 parts of normal saline and 1 part of camellia extract.
Wherein the molecular weight of hyaluronic acid is 30000 daltons, the sodium hyaluronate comprises medium molecular weight sodium hyaluronate and small molecular weight sodium hyaluronate with the mass ratio of 1:10-and the molecular weight of the medium molecular weight sodium hyaluronate is 100 ten thousand daltons, and the molecular weight of the small molecular weight sodium hyaluronate is 8000 daltons.
Wherein, the camellia extract is obtained by the following method: cleaning flos Camelliae Japonicae, mixing with 20 times of water, boiling for 30min, filtering, and freeze preserving.
The injection composition for removing wrinkles in this example was prepared by the following method:
preparing tea flower extract, mixing and stirring with glycerol, growth factors and physiological saline at 6 ℃ to obtain a functional buffer solution;
after the hexapeptide and the sodium hyaluronate are uniformly mixed, hyaluronic acid and a functional buffer solution are added, and after radiation sterilization, the injection composition for removing wrinkles is prepared.
Example 6
The embodiment provides an injection composition for removing wrinkles, which comprises the following raw materials in parts by weight:
2.5 parts of hyaluronic acid, 2 parts of sodium hyaluronate, 0.3 part of growth factor, 0.07 part of hexapeptide, 10 parts of glycerol, 94 parts of physiological saline, 1 part of camellia extract and 0.1 part of vitamin C.
Wherein the molecular weight of hyaluronic acid is 20000 daltons, the sodium hyaluronate comprises medium molecular weight sodium hyaluronate and small molecular weight sodium hyaluronate with a mass ratio of 1:20, the molecular weight of the medium molecular weight sodium hyaluronate is 110 ten thousand daltons, and the molecular weight of the small molecular weight sodium hyaluronate is 5000 daltons.
Wherein, the camellia extract is obtained by the following method: cleaning flos Camelliae Japonicae, mixing with 10 times of water, boiling for 30min, filtering, and freeze preserving.
The injection composition for removing wrinkles in this example was prepared by the following method:
preparing tea flower extract, mixing and stirring with glycerol, growth factors and normal saline at 8 ℃ to obtain a functional buffer solution;
after the hexapeptide and the sodium hyaluronate are uniformly mixed, hyaluronic acid and a functional buffer solution are added, and after radiation sterilization, the injection composition for removing wrinkles is prepared.
Comparative example 1
This comparative example provides an injectable composition comprising 25% hyaluronic acid, 10% mannitol and 75% aqueous solution for injection.
Comparative example 2
The comparative example provides an injection composition, which comprises 9 parts by weight of sodium hyaluronate, 0.5 part by weight of growth factor, 0.01 part by weight of hexapeptide, 10 parts by weight of glycerol, 80 parts by weight of physiological saline and 1 part by weight of camellia extract.
Comparative example 3
The comparative example provides an injection composition, which comprises 9 parts of hyaluronic acid, 0.5 part of growth factor, 0.01 part of hexapeptide, 10 parts of glycerol, 80 parts of normal saline and 1 part of camellia extract by weight.
Comparative example 4
The comparative example provides an injection composition comprising, by weight, 4 parts of hyaluronic acid, 1 part of sodium hyaluronate, 0.01 part of hexapeptide, 10 parts of glycerol and 80 parts of physiological saline.
Comparative example 5
The comparative example provides an injection composition comprising, by weight, 4 parts of hyaluronic acid, 1 part of sodium hyaluronate, 0.5 part of a growth factor, 10 parts of glycerol and 80 parts of physiological saline.
Comparative example 6
The comparative example provides an injection composition comprising, by weight, 4 parts of hyaluronic acid, 1 part of sodium hyaluronate, 1.0 part of a growth factor, 0.2 part of hexapeptide, 10 parts of glycerol and 80 parts of physiological saline.
Comparative example 7
The comparative example provides an injection composition, which comprises, by weight, 4 parts of hyaluronic acid, 1 part of sodium hyaluronate, 0.5 part of a growth factor, 0.01 part of hexapeptide, 10 parts of glycerol, 80 parts of normal saline and 1 part of camellia extract. The sodium hyaluronate in this comparative example was sodium hyaluronate of medium molecular weight of 100 kilodaltons.
The raw materials of comparative examples 1 to 7 were directly mixed at normal temperature to obtain an injection composition.
Test example 1 cytotoxicity test
The injections provided in examples 1 to 6 and comparative examples 1 to 7 were subjected to cytotoxicity test by MTT method. Cytotoxicity reference GB/T16886.5-2017, section 5, medical device biology evaluation: in vitro cytotoxicity test (Ex vivo cytotoxicity test) examined the survival of cells after addition of different groups of injections. The relative proliferation rate of cells was converted to a 5-stage reaction to assess sample toxicity, the negative control was PBS and the positive control was zinc diethyldithiocarbamate.
TABLE 1 cytotoxicity test results
| Group of | Value-added rate | Toxicity grade |
| Example 1 | 98.6％ | Level 1 |
| Example 2 | 96.1％ | Level 1 |
| Example 3 | 90.8％ | Level 1 |
| Example 4 | 92.3％ | Level 1 |
| Example 5 | 91.4％ | Level 1 |
| Example 6 | 94.7％ | Level 1 |
| Comparative example 1 | 30.1％ | Level 1 |
| Comparative example 2 | 66.7％ | Level 1 |
| Comparative example 3 | 45.9％ | Level 1 |
| Comparative example 4 | 34.6％ | Level 2 |
| Comparative example 5 | 37.8％ | Level 2 |
| Comparative example 6 | 47.2％ | 3 grade |
| Comparative example 7 | 78.8％ | Level 1 |
| Negative control | 100％ | Level 0 |
| Positive control | 20.6％ | Grade 4 |
Test example 2-irritation test
The following experiments were performed by randomly dividing 130 female testers between 20 and 30 years old into 13 groups of 10. The injections prepared in examples 1 to 6 and comparative examples 1 to 7 were directly applied to the skin of the hands with a substantially uniform application area. After 30 minutes, the skin irritation of the injection was evaluated.
TABLE 2 results of irritation experiments
It can be seen that the injection composition for removing wrinkles disclosed by the application has higher safety performance, and the formula is mild and has no irritation, and can not cause the phenomena of redness and swelling and pimple formation on skin.
Test example 3 injection safety
To determine the safety and biocompatibility of the injections, the injections of example 1 and comparative examples 1-7 were subcutaneously injected into mice, and two mice were injected into each group as parallel.
TABLE 3 in vivo experiments in mice
In the table, "/indicates that the mice are normal in state, have no adverse reactions such as anorexia and the like, and have no phenomena such as reddening, swelling, pimple and the like; "#" indicates that the mice had an uncomfortable response and had a slight bulge; "×" indicates that the mice were abnormal, had a large red swelling, and were relatively frightened.
The formula of the application obviously has better biocompatibility and safety.
Test example 4 moisturizing and wrinkle removing Effect
6 volunteers willing to receive the experiment were found, three men and three women, respectively, with an average age of 36.8. The injections of examples 1 to 6 were directly injected onto the skin of the hand, respectively, and the moisture content was measured with a skin moisture meter while observing changes in skin wrinkles with naked eyes.
TABLE 4 moisturizing and wrinkle removing effects
| Water content before injection | Water content after 30min of injection | Water content after 2h of injection | Water content after 8h of injection | |
| Example 1 | 40±5 | 51±5 | 97±5 | 84±5 |
| Example 2 | 45±5 | 62±5 | 90±5 | 80±5 |
| Example 3 | 50±5 | 63±5 | 87±5 | 79±5 |
| Example 4 | 48±5 | 71±5 | 88±5 | 81±5 |
| Example 5 | 50±5 | 63±5 | 90±5 | 85±5 |
| Example 6 | 41±5 | 49±5 | 91±5 | 90±5 |
Meanwhile, the 6 volunteers feed back according to the original camera photos before and after injection and the fold change condition of the skin after injection for 3 days, and all acknowledge that the wrinkle condition of the injection part is improved to a certain extent, and the smaller the age, the better the improvement condition.
In conclusion, the injection composition for removing wrinkles disclosed by the application has good effect on removing wrinkles of skin, has good biocompatibility and biological absorbability, is mild and non-irritating, and does not generate any toxic or side effect on human bodies. Meanwhile, the skin can reach full, compact, bright and beautiful youthful vigor state, and the skin has the characteristics of natural effect, convenience in use and the like.
Various embodiments of the application may exist in a range of forms; it should be understood that the description in a range format is merely for convenience and brevity and should not be construed as a rigid limitation on the scope of the application; it is therefore to be understood that the range description has specifically disclosed all possible sub-ranges and individual values within that range. For example, it should be considered that a description of a range from 1 to 6 has specifically disclosed sub-ranges, such as from 1 to 3, from 1 to 4, from 1 to 5, from 2 to 4, from 2 to 6, from 3 to 6, etc., as well as single numbers within the range, such as 1, 2, 3, 4, 5, and 6, wherever applicable. In addition, whenever a numerical range is referred to herein, it is meant to include any reference number (fractional or integer) within the indicated range.
The foregoing is only a specific embodiment of the application to enable those skilled in the art to understand or practice the application. Various modifications to these embodiments will be readily apparent to those skilled in the art, and the generic principles defined herein may be applied to other embodiments without departing from the spirit or scope of the application. Thus, the present application is not intended to be limited to the embodiments shown herein but is to be accorded the widest scope consistent with the principles and novel features disclosed herein.
Claims (10)
1. An injection composition for removing wrinkles is characterized by comprising hyaluronic acid, sodium hyaluronate, growth factors, hexapeptide, glycerol, physiological saline and camellia extract.
2. The wrinkle-removing injectable composition according to claim 1, wherein the mass ratio of hyaluronic acid, sodium hyaluronate and camellia extract is 1-4:1-3:1.
3. The injection composition for removing wrinkles according to claim 1, wherein the mass ratio of the growth factor, the hexapeptide and the glycerol is 0.01-0.5:0.01-0.1:5-10, and the mass fraction of the physiological saline is 50-95%.
4. The wrinkle-removing injectable composition according to claim 1, comprising the following raw materials in parts by weight:
1 to 4 parts of hyaluronic acid, 1 to 3 parts of sodium hyaluronate, 0.01 to 0.5 part of growth factor, 0.01 to 0.1 part of hexapeptide, 5 to 10 parts of glycerol, 50 to 95 parts of normal saline and 1 part of camellia extract.
5. The wrinkle-removing injectable composition according to claim 4, comprising the following raw materials in parts by weight:
4 parts of hyaluronic acid, 1 part of sodium hyaluronate, 0.5 part of growth factor, 0.01 part of hexapeptide, 10 parts of glycerol, 80 parts of normal saline and 1 part of camellia extract.
6. The injection composition for removing wrinkles according to claim 1, wherein the camellia extract is an aqueous extract of camellia obtained by mixing with water, boiling extraction, filtration, and freeze preservation.
7. The injection composition for removing wrinkles according to claim 1, wherein the sodium hyaluronate comprises medium molecular weight sodium hyaluronate and small molecular weight sodium hyaluronate in a mass ratio of 1:10 to 20, wherein the medium molecular weight sodium hyaluronate has a molecular weight of 100 to 120 ten thousand daltons and the small molecular weight sodium hyaluronate has a molecular weight of 3000 to 8000 daltons.
8. The wrinkle removing injectable composition according to claim 1, wherein the hyaluronic acid has a molecular weight of 10000 to 30000 daltons.
9. The wrinkle-removing injectable composition according to claim 1, further comprising vitamins.
10. A method of preparing an injectable composition for wrinkle removal according to any one of claims 1 to 9, comprising the steps of:
preparing tea flower extract, mixing and stirring the tea flower extract with glycerol, growth factors and physiological saline at the temperature of 5-10 ℃ to obtain a functional buffer solution;
after the hexapeptide and the sodium hyaluronate are uniformly mixed, hyaluronic acid and a functional buffer solution are added, and after radiation sterilization, the injection composition for removing wrinkles is prepared.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202310825559.7A CN116687799A (en) | 2023-07-06 | 2023-07-06 | Injection composition for removing wrinkles and preparation method thereof |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202310825559.7A CN116687799A (en) | 2023-07-06 | 2023-07-06 | Injection composition for removing wrinkles and preparation method thereof |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN116687799A true CN116687799A (en) | 2023-09-05 |
Family
ID=87825820
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN202310825559.7A Pending CN116687799A (en) | 2023-07-06 | 2023-07-06 | Injection composition for removing wrinkles and preparation method thereof |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN116687799A (en) |
-
2023
- 2023-07-06 CN CN202310825559.7A patent/CN116687799A/en active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN106137786B (en) | A kind of anti-ageing composition of hyaluronic acid and its preparation method and application | |
| JP2021100603A (en) | Dermal filler compositions comprising antioxidant | |
| KR102265076B1 (en) | Dermal filler compositions | |
| CN107375032B (en) | Composition for repairing skin barrier and preparation method thereof | |
| KR20190100979A (en) | Dermal filler compositions including antioxidants | |
| KR101582660B1 (en) | Hydrogel Mask Pack Production Containing Collagen Using Radiation | |
| CN111110623A (en) | Self-repairing small needle nutrient solution formula | |
| CN105662981A (en) | Dual-effect cure essence | |
| JP7074951B2 (en) | Silicone oil-in-water composition useful as an injectable filler and as a scaffold for collagen growth | |
| WO2014044808A2 (en) | Fast-penetration cosmetic dermal filler for topical application | |
| CN111297727A (en) | Beautifying and plasticizing treatment composition and application thereof | |
| CN105662916B (en) | A kind of sebum film remediation composition | |
| CN104546639B (en) | A kind of stem cell essence and preparation method thereof | |
| CN107137760A (en) | A kind of moisturizing maintenance dressing and preparation method thereof | |
| CN107213028A (en) | A kind of collagen implant and preparation method thereof | |
| CN108686255A (en) | It is a kind of to prevent the biological dressing and preparation method thereof that scar is formed | |
| CN109350591A (en) | A kind of U.S. face dried noodle film and preparation method thereof | |
| KR20170012810A (en) | Hydrogel pack comprising natural petals | |
| CN111494238A (en) | Repairing and moistening mask containing carboxylated chitosan and preparation method thereof | |
| CN116942559A (en) | Smearing type wrinkle-removing composition and application thereof | |
| RU2383341C2 (en) | Method of skin rejuvenation | |
| CN108743921A (en) | It is a kind of to prevent the reparation liquid and its preparation method and application that scar is formed | |
| KR20230049560A (en) | Cosmetic composition for improvement of skin derived from natural products | |
| CN114159341B (en) | Freeze-dried eye patch and preparation method thereof | |
| CN116687799A (en) | Injection composition for removing wrinkles and preparation method thereof |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination |